Precision Biopsy: FDA OKs expanded trial for Precision Biopsy's ClariCore prostate biopsy device

Precision Biopsy said today it won an investigational device exemption from the FDA to expand the trial of its ClariCore biopsy system, now looking to enroll prostate cancer patients in the newly cleared Transrectal Ultrasound and MR/Fusion arms of the study. The ClariCore system is designed for the spectral analysis of tissue samples during biopsies to "rapidly [...]The post FDA OKs expanded trial for Precision Biopsy's ClariCore prostate biopsy device appeared first on MassDevice.